Management of Diabetes and Advanced Chronic Kidney Disease

Introduction to Management

• The American College of Cardiology recommends initiating an SGLT2 inhibitor as first-line therapy for patients with type 2 diabetes and CKD stage G4, due to its cardiorenal protective effects, independent of glucose-lowering effects 1
• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that SGLT2 inhibitors can be continued down to an eGFR of ≥20 mL/min/1.73 m², providing cardiovascular benefits and reducing albuminuria 4, 5

Critical Lab Findings Requiring Action

• A patient with an eGFR of 19 mL/min/1.73 m² has stage G4 CKD, indicating a need for renal replacement therapy planning, according to the National Kidney Foundation 2
• Significant proteinuria (2+ proteinuria) requires the initiation of RAS blockade, such as an ACE inhibitor or ARB, to slow CKD progression, as recommended by the Kidney International journal 3

Immediate Pharmacological Management

• The American Diabetes Association recommends initiating a long-acting GLP-1 receptor agonist, such as dulaglutide or semaglutide, for patients with type 2 diabetes and CKD, given its cardiovascular benefits and low hypoglycemia risk 5, 7
• The European Society of Cardiology suggests that GLP-1 receptor agonists can be used safely at an eGFR as low as 15 mL/min/1.73 m², providing cardiovascular protection and reducing albuminuria 6

RAS Blockade for Proteinuria

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend initiating an ACE inhibitor or ARB immediately for patients with significant proteinuria (2+ proteinuria), to slow CKD progression and reduce albuminuria 3, 1

Cardiovascular Risk Reduction

• The American College of Cardiology recommends initiating high-intensity statin therapy for patients with diabetes and CKD, regardless of baseline LDL levels, to reduce cardiovascular risk 1

Glycemic Targets and Monitoring

• The American Diabetes Association recommends an individualized HbA1c target of <7.0% to <7.5% for patients with type 2 diabetes and CKD, to balance the benefits of glycemic control with the risks of hypoglycemia 2, 1

Lifestyle Interventions

• The Academy of Nutrition and Dietetics recommends a protein intake of 0.8 g/kg/day for patients with CKD, to reduce the risk of malnutrition and slow CKD progression 2, 4, 7
• The American Heart Association suggests a sodium intake of <2 g/day (<5 g sodium chloride/day) to reduce blood pressure and slow CKD progression 2, 4, 7

Additional Management

• The Endocrine Society recommends vitamin D supplementation (cholecalciferol 1000-2000 IU daily) for patients with CKD and low vitamin D levels, to reduce the risk of CKD-mineral bone disorder 1

Monitoring Schedule

• The National Kidney Foundation recommends monitoring eGFR and creatinine every 2-4 weeks after medication changes, then every 3 months, to assess renal function and adjust therapy as needed 1
• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest monitoring potassium every 2-4 weeks after RAS blockade initiation, then every 3 months, to reduce the risk of hyperkalemia 3